Yui K - Search Results

1

Oxidative Stress and Nitric Oxide in Autism Spectrum Disorder and Other Neuropsychiatric Disorders.

Yui K, Kawasaki Y, Yamada H, Ogawa S. Yui K, et al. CNS Neurol Disord Drug Targets. 2016;15(5):587-96. doi: 10.2174/1871527315666160413121751. CNS Neurol Disord Drug Targets. 2016. PMID: 27071787 Review.

2

Psycho-Cognitive Intervention for ASD from Cross-Species Behavioral Analyses of Infants, Chicks and Common Marmosets.

Koshiba M, Karino G, Mimura K, Nakamura S, Yui K, Kunikata T, Yamanouchi H. Koshiba M, et al. Among authors: yui k. CNS Neurol Disord Drug Targets. 2016;15(5):578-86. doi: 10.2174/1871527315666160413121613. CNS Neurol Disord Drug Targets. 2016. PMID: 27071788

3

Competitive Interaction Between Plasma Omega-3 Fatty Acids and Arachidonic Acid is Related to Down-Regulation of A Signaling Mediator.

Yui K, Imataka G, Kawasaki Y. Yui K, et al. Med Chem. 2016;12(4):318-27. doi: 10.2174/1573406412666160107113725. Med Chem. 2016. PMID: 26740205

4

Increased ω-3 polyunsaturated fatty acid/arachidonic acid ratios and upregulation of signaling mediator in individuals with autism spectrum disorders.

Yui K, Imataka G, Kawasak Y, Yamada H. Yui K, et al. Life Sci. 2016 Jan 15;145:205-12. doi: 10.1016/j.lfs.2015.12.039. Epub 2015 Dec 24. Life Sci. 2016. PMID: 26724495

5

Editorial. New Targets of Medical Treatment in Psychiatric Disorders.

Yui K. Yui K. Curr Neuropharmacol. 2015;13(6):736-8. doi: 10.2174/1570159x1306151126144423. Curr Neuropharmacol. 2015. PMID: 26630953 Free PMC article. No abstract available.

6

Down-regulation of a signaling mediator in association with lowered plasma arachidonic acid levels in individuals with autism spectrum disorders.

Yui K, Imataka G, Kawasaki Y, Yamada H. Yui K, et al. Neurosci Lett. 2016 Jan 1;610:223-8. doi: 10.1016/j.neulet.2015.11.006. Epub 2015 Nov 10. Neurosci Lett. 2016. PMID: 26552013

7

Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders.

Yui K, Imataka G, Nakamura H, Ohara N, Naito Y. Yui K, et al. Curr Neuropharmacol. 2015;13(6):776-85. doi: 10.2174/1570159x13666151102103305. Curr Neuropharmacol. 2015. PMID: 26521945 Free PMC article. Review.

8

[Useful pharmacologic treatment in impaired social interaction in autism spectrum disorders].

Yui K. Yui K. Seishin Shinkeigaku Zasshi. 2012;114(8):934-40. Seishin Shinkeigaku Zasshi. 2012. PMID: 23012855 Japanese.

9

[Therapeutic effects of larger doses of arachidonic acid added to DHA on social impairment and its relation to alterations of polyunsaturated fatty acids in individuals with autism spectrum disorders].

Yui K, Koshiba M, Nakamura S, Onishi M. Yui K, et al. Nihon Shinkei Seishin Yakurigaku Zasshi. 2011 Jun;31(3):117-24. Nihon Shinkei Seishin Yakurigaku Zasshi. 2011. PMID: 21800702 Review. Japanese.

10

Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: a double-blind, placebo-controlled, randomized trial.

Yui K, Koshiba M, Nakamura S, Kobayashi Y. Yui K, et al. J Clin Psychopharmacol. 2012 Apr;32(2):200-6. doi: 10.1097/JCP.0b013e3182485791. J Clin Psychopharmacol. 2012. PMID: 22370992 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results